Ostarine will be the closest SARM to remaining authorized in medicine and it is at the moment in stage II clinical trials. Like SARMs generally speaking, MK-2866 targets androgen receptors with a selective basis and avoids making the forms of harmful side effects related with substances like testosterone, human growth https://indirav987lcr6.ageeksblog.com/profile